← FDA DRUG APPROVALS

FDA NDA · NDA214952

LIQREV

Sponsor: CMP DEV LLC

APPLICATION
NDA214952
TYPE
NDA
ORIGINAL APPROVAL
2023-04-28
LATEST ACTION
2023-04-28
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

LIQREV · ReferenceDiscontinued
SILDENAFIL CITRATE EQ 10MG BASE/ML · SUSPENSION · ORAL

Approval history

2023-04-28Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →